Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer

Drug Metabolism and Disposition

Volumn 36, Issue 2, 2008, Pages 205-216

  Morgan, Edward T ^a   Goralski, Kerry B ^b,c   Piquette Miller, Micheline ^d   Renton, Kenneth W ^b   Robertson, Graham R ^e   Chaluvadi, Madhusudana R ^a   Charles, Kellie A ^f   Clarke, Stephen J ^e   Kacevska, Marina ^e   Liddle, Christopher ^f   Richardson, Terrilyn A ^a   Sharma, Rohini ^f   Sinal, Christopher J ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ANZAC RESEARCH INSTITUTE   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTHRACENE DERIVATIVE; ANTHRACYCLINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTERONE; CYCLOSPORIN A; CYTOCHROME P450; DEXAMETHASONE; DIGOXIN; DILTIAZEM; DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; NELFINAVIR; PREDNISOLONE; QUINIDINE; RITONAVIR; SAQUINAVIR; TACROLIMUS; TAXANE DERIVATIVE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERAPAMIL; VINCA ALKALOID;

AGITATION; BACTERIAL INFECTION; CANCER PATIENT; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; HUMAN; INFLAMMATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INFECTION; INFLAMMATION; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; TRANSCRIPTION, GENETIC;

BACTERIA (MICROORGANISMS);

EID: 38749091688     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.018747     Document Type: Conference Paper

References (63)

1. Abdulla D, Goralski KB, and Renton KW (2006) The regulation of cytochrome P450 2E1 during LPS-induced inflammation in the rat. Toxicol Appl Pharmacol 216:1-10.
2. Aitken AE, Richardson TA, and Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149.
3. Azri S, and Renton KW (1987) Depression of murine hepatic mixed function oxidase during infection with Listeria monocytogenes. J Pharmacol Exp Ther 243:1089-1094.
4. Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, et al. (2004) Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10:8341-8350.
5. Beaulieu E, Demeule M, Ghitescu L, and Beliveau R (1997) P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 326 (Pt 2):539-544.
6. Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, and Feingold KR (2002) Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem Biophys Res Commun 293:145-149.
7. Brozek W, Bises G, Girsch T, Cross HS, Kaiser HE, and Peterlik M (2005) Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. Eur J Cancer 41:2347-2354.
8. Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, and Robertson GR (2006) Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res 12:7492-7497.
9. Chen JQ, Strom A, Gustafsson JA, and Morgan ET (1995) Suppression of the constitutive expression of cytochrome P-450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the suppressive response to interleukins 1 and 6. Mol Pharmacol 47:940-947.
10. Cheng PY, Wang M, and Morgan ET (2003) Rapid transcriptional suppression of rat cytochrome P450 genes by endotoxin treatment and its inhibition by curcumin. J Pharmacol Exp Ther 307:1205-1212.
11. de Vries HE, Kuiper J, de Boer AG, Van Berkel TJ, and Breimer DD (1997) The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev 49:143-155.
12. Ferrari L, Peng N, Halpert JR, and Morgan ET (2001) Role of nitric oxide in down-regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes. Mol Pharmacol 60:209-216.
13. Garcia Del Busto Cano E and Renton KW (2003) Modulation of hepatic cytochrome P450 during Listeria monocytogenes infection of the brain. J Pharm Sci 92:1860-1868.
14. Goralski KB, Abdulla D, Sinal CJ, Arsenault A, and Renton KW (2005) Toll-like receptor-4 regulation of hepatic Cyp3a11 metabolism in a mouse model of LPS-induced CNS inflammation. Am J Physiol 289:G434-G443.
15. Goralski KB, Acott PD, Fraser AD, Worth D, and Sinal CJ (2006) Brain cyclosporin A levels are determined by ontogenic regulation of mdr1a expression. Drug Metab Dispos 34:288-295.
16. Goralski KB, Hartmann G, Piquette-Miller M, and Renton KW (2003) Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol 139:35-48.
17. Goralski KB and Renton KW (2004) Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats. Toxicol Appl Pharmacol 196:381-389.
18. Hartmann G, Cheung AK, and Piquette-Miller M (2002) Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther 303:273-281.
19. Hartmann G, Kim H, and Piquette-Miller M (2001) Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int Immunopharmacol 1:189-199.
20. Hartmann G, Vassileva V, and Piquette-Miller M (2005) Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab Dispos 33:820-828.
21. Hartz AM, Bauer B, Fricker G, and Miller DS (2006) Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-α and lipopolysaccharide. Mol Pharmacol 69:462-470.
22. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano L, Locatelli A, Verweij J, et al. (2005) Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11:8097-8104.
23. Ho EA and Piquette-Miller M (2007) KLF6 and HSF4 transcriptionally regulate multidrug resistance transporters during inflammation. Biochem Biophys Res Commun 353:679-685.
24. Jover R, Bort R, Gómez-Lechón MJ, and Castell JV (2002) Down-regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved. FASEB J 16:1799-1801.
25. Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, and Piquette-Miller M (2004) Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos 32:20-27.
26. Knickle LC, Spencer DF, and Renton KW (1992) The suppression of hepatic cytochrome P4504A mRNA mediated by the interferon inducer polyinosinic acid · polycytidylic acid. Biochem Pharmacol 44:604-608.
27. Kraemer MJ, Furukawa CT, Koup JR, Shapiro GG, Pierson WE, and Bierman CW (1982) Altered theophylline clearance during an influenza B outbreak. Pediatrics 69:476-480.
28. Laflamme N and Rivest S (2001) Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. FASEB J 15:155-163.
29. Lee G and Piquette-Miller M (2001) Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol 79:876-884.
30. Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, et al. (2005) Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 11:7398-7404.
31. Letrent SP, Pollack GM, Brouwer KR, and Brouwer KL (1999a) Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 27:827-834.
32. Letrent SP, Polli JW, Humphreys JE, Pollack GM, Brouwer KR, and Brouwer KL (1999b) P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem Pharmacol 58:951-957.
33. Lötsch J, Schmidt R, Vetter G, Schmidt H, Niederberger E, Geisslinger G, and Tegeder I (2002) Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J Neurochem 83:241-248.
34. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, and Billiar TR (2006) Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock 26:430-437.
35. Morgan ET (1997) Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29:1129-1188.
36. Morgan ET, Li-Masters T, and Cheng PY (2002) Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology 181-182:207-210.
37. Nicholson TE and Renton KW (2001) Role of cytokines in the lipopolysaccharide-evoked depression of cytochrome P450 in the brain and liver. Biochem Pharmacol 62:1709-1717.
38. Peterson TC and Renton KW (1986) Kupffer cell factor mediated depression of hepatic parenchymal cell cytochrome P-450. Biochem Pharmacol 35:1491-1497.
39. Petrovic V, Teng S, and Piquette-Miller M (2007) Regulation of drug transporters during infection and inflammation. Mol Interv 7:99-111.
40. Piquette-Miller M, Pak A, Kim H, Anari R, and Shahzamani A (1998) Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharmacol Res 15:706-711.
41. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088.
42. Renton KW (2001) Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147-163.
43. Renton KW (2004) Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5:235-243.
44. Renton KW (2005) Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 1:629-640.
45. Renton KW and Mannering GJ (1976a) Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents. Biochem Biophys Res Commun 73:343-348.
46. Renton KW and Mannering GJ (1976b) Depression of the hepatic cytochrome P-450 monooxygenase system by administered tilorone (2,7-bis(2-(diethylamino) ethoxy)fluoren-9-one dihydrochloride). Drug Metab Dispos 4:223-231.
47. Renton KW and Nicholson TE (2000) Hepatic and central nervous system cytochrome P450 are down-regulated during lipopolysaccharide-evoked localized inflammation in brain. J Pharmacol Exp Ther 294:524-530.
48. Richardson TA and Morgan ET (2005) Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice. J Pharmacol Exp Ther 314:703-709.
49. Richardson TA, Sherman M, Antonovic L, Kardar SS, Strobel HW, Kalman D, and Morgan ET (2006) Hepatic and renal cytochrome P450 gene regulation during Citrobacter rodentium infection in wild-type and Toll-like receptor 4 mutant mice. Drug Metab Dispos 34:354-360.
50. Robertson GR, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, and Liddle C (2003) Transgenic mouse models of human CYP3A4 gene regulation. Mol Pharmacol 64:42-50.
51. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, and de Miguel MP (2004) Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplastic, and malignant human prostate. J Pathol 202:41-49.
52. Scheld WM, Koedel U, Nathan B, and Pfister HW (2002) Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J Infect Dis 186 (Suppl 2):S225-S233.
53. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
54. Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, and Jover R (2000) Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 32:49-55.
55. Singh G and Renton KW (1984) Inhibition of the synthesis of hepatic cytochrome P-450 by the interferon-inducing agent poly rI · rCi. Can J Physiol Pharmacol 62:379-383.
56. Singh G, Renton KW, and Stebbing N (1982) Homogeneous interferon from E. coli depresses hepatic cytochrome P-450 and drug biotransformation. Biochem Biophys Res Commun 106: 1256-1261.
57. Slaviero KA, Clarke SJ, and Rivory LP (2003) Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 4:224-232.
58. Sukhai M, Yong A, Kalitsky J, and Piquette-Miller M (2000) Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the mdr1a and mdr1b Genes. Mol Cell Biol Res Commun 4:248-256.
59. Sweet MJ and Hume DA (1996) Endotoxin signal transduction in macrophages. J Leukoc Biol 60:8-26.
60. Tang W, Yi C, Kalitsky J, and Piquette-Miller M (2000) Endotoxin downregulates hepatic expression of P-glycoprotein and MRP2 in 2-acetylaminofluorene-treated rats. Mol Cell Biol Res Commun 4:90-97.
61. Teng S and Piquette-Miller M (2005) The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J Pharmacol Exp Ther 312:841-848.
62. Vuppugalla R and Mehvar R (2005) Enzyme-selective effects of nitric oxide on affinity and maximum velocity of various rat cytochromes P450. Drug Metab Dispos 32:1446-1454.
63. 99mTc- sestamibi imaging. J Nucl Med 46:1537-1545.